Anthrax
Methodology & AI Transparency ⓘ
Anthrax Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil.
- 2 Real-world patient consensus: Mapped to Asthma, COPD & Respiratory Disease under ICD-10-CM J43.4 for Anthrax clinical workups.
- 3 Typical cash cost range: Differential triage of Anthrax (J43.4) utilizes vaccination review [Anthrax J43.4].
- 4 Top reported side effects / signs: Key Lungs & Asthma biomarkers for Anthrax (J43.4): Resting Pulse Oximetry in Anthrax (J43.4: (SpO2)) & Blood Eosinophil Count [Anthrax J43.4] (< 150 cells/uL (phenotyping marker) (J43.4)).
Ask our AI Specialists anything about Anthrax
What Is Anthrax?
Anthrax is a disease caused by Bacillus anthracis, a germ that lives in soil. Many people know about it from the 2001 bioterror attacks. In the attacks, someone purposely spread anthrax through the U.S. mail. This killed five people and made 22 sick. Anthrax is rare. It affects animals such as cattle, sheep, and goats more often than people. People can get anthrax from contact with infected animals, wool, meat, or hides. It can cause three forms of disease in people. They are: Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria. Inhalation, which affects the lungs.
Pathophysiology, Underlying Causes & Clinical Presentation
Anthrax (J43.4) alters lungs & asthma homeostasis through eosinophilic or neutrophilic in Anthrax (J43.4: airway mucosal inflammation); Cross-referenced with NIH MeSH (Anthrax Vaccines, Anthrax), clinical remission targets Blood Eosinophil Count [Anthrax J43.4] within < 150 cells/uL (phenotyping marker) (J43.4).
Common Symptoms & Clinical Signs
- • Cutaneous, which affects the skin. People with cuts or open sores can get it if they touch the bacteria
- • Inhalation, which affects the lungs. You can get this if you breathe in spores of the bacteria
- • Presentation of Anthrax (J43.4): prolonged recovery from in Anthrax (J43.4: viral respiratory infections)
- • Secondary Anthrax clinical sign: declining stair-climbing stamina in Anthrax (J43.4: or frequent rescue)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Anthrax Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J43.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Resting Pulse Oximetry in Anthrax (J43.4: (SpO2)) | 96% – 100% (J43.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Anthrax J43.4] | < 150 cells/uL (phenotyping marker) (J43.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Anthrax (J43.4: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (J43.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Anthrax
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Anthim (Obiltoxaximab) Anthim • RxCUI RXN-B69604204 | Anthrax Protective Antigen-directed Antibody | 74% | $1.8900 | $ 144.58 /mo |
| Raxibacumab Raxibacumab Generic • RxCUI RXN-71655103-3229 | Anthrax Protective Antigen-directed Antibody | 82% | $0.5000 | $ 28.75 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Anthrax)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed,: What a 3,689-Participant Study Found The study met the pre-defined endpoint criteria, demonstrating protective level of immune response and non-inferiority of CYFENDUS to BioThrax vaccination. Vaccine • 2026-02-06 • Phase III Randomized Trial | N = 3,689 | 96/100 | PMID 41401704 ↗ |
| New Insights on Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and: What a 8,509-Participant Study Found BGF triple therapy improved symptoms and HRQoL vs dual therapies over 24 and 52 weeks in patients with moderate-to-very severe COPD. Respiratory medicine • 2021-01-15 • Phase III Randomized Trial | N = 8,509 | 96/100 | PMID 34171789 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of exacerbation history on clinical response to dupilumab in Dupilumab significantly reduced severe exacerbations and improved FEV 1 and asthma control in patients with elevated type 2 biomarkers irrespective of exacerbation history and baseline ICS dose. The European respiratory journal • 2021-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34266940 ↗ |
Anthrax Patient Community & “People Like Me” Threads
Filter Anthrax community threads and patient logs by age, biological sex, dosage, and treatment duration.
Tracking Resting Pulse Oximetry in Anthrax (J43.4: (SpO2)) every 12 weeks for Anthrax: what lab cadence worked best?
FDA/PubMed Clinical Context Note: Clinical guidelines across Asthma, COPD & Respiratory Disease (Anthrax, ICD-10-CM J43.4) generally pair 8-to-12-week repeat biomarker verification (Resting Pulse Oximetry in Anthrax (J43.4: (SpO2)): 96% – 100% (J43.4)) with symptom review so steady-state physiological response is captured accurately.
After being diagnosed with Anthrax (ICD-10 J43.4), my clinician and I set a goal around Resting Pulse Oximetry in Anthrax (J43.4: (SpO2)) (96% – 100% (J43.4)) before escalating medication doses. For others managing lungs & asthma markers, did quarterly bloodwork catch changes early enough without over-testing?
12-week intervals worked really well for tracking Resting Pulse Oximetry in Anthrax (J43.4: (SpO2)). Using the same morning fasting draw window each quarter eliminated day-to-day noise so my doctor could adjust cleanly.
Ordering Resting Pulse Oximetry in Anthrax (J43.4: (SpO2)) alongside standard preventive labs prior to my follow-up visit saved an extra co-pay and kept our appointment focused on actual trend lines.